Searched for
GAGILLAPUR FACILITY
Can Granules India leverage its strong product pipeline to offset recent profit declines?Granules India's stock shows a slight recovery despite reporting lower profits in the June quarter. Investors are positive about the compan...- Buy, Sell or Hold: Motilal Oswal reiterates buy on JSPL; Nuvama sees 18% upside in NMDCBrokerages are optimistic about Jindal Steel & Power, Granules India, and NMDC, citing strong growth prospects. Motilal Oswal highlights Ji...
- Stocks in news: SpiceJet, Shriram Finance, Suven Pharma, Mazagon Dock, Suzlon EnergyStocks in news: Equity markets ended a three-week winning streak with a loss of over 1.5%, influenced by weak global cues. Key stocks in fo...
- Granules India gets Health Canada nod to market arthritis tabletsThe drug will be manufactured at the company's manufacturing facility located in Gagillapur, Hyderabad, the filing said.
- USFDA issues EIR for Granules India's Gagillapur plantFinished dosages and pharmaceutical formulation intermediates are manufactured at the plant, it said. Granules India stock was trading near...
- Hits & misses: Rs 7 lakh in this stock for 7 years could have made you crorepatiOne such miss is Granules India. An initial investment of around Rs 7 lakh (Rs 6,88,550) in the stock seven years ago could have made you a...
- Granules India surges 7% on successful completion of re-inspection at Telangana facilityThe company had in January received eleven observations from Infarmed, the Portuguese drug regulator, for its facility located at Gagillapu...
- OmniChem will grow at not less than 20 per cent: Krishna Prasad, CMG, Granules IndiaWe estimate that OmniChem is going to do anywhere from 180-200 crores revenues with an EBITDA of not less than 20 per cent.
- Granules India slips on receiving 11 observations from Portuguese drug regulatorAt 10:00 am; Granules India was trading 6 per cent lower at Rs 104.60. It hit a low of Rs 97.75 and a high of Rs 107.40 in the first 45-min...
- Generis buy should be good for Aurobindo Pharma: Surajit Pal, Prabhudas LiladherMy problem with a company like Granules is that I really cannot bet on a company which is betting highly on a highly commoditised product, ...
- Ten stocks in focus on Monday, 9 January 20178K Miles Software will announce its financial results for the quarter ended December 31, 2016 on Monday.
- Gagillapur unit contributes over 50 per cent to revenues: C Krishna Prasad of Granules IndiaThe main growth, the boost for growth of Granules India from now on would be in complex molecules and extended release, controlled release ...
- Granules India shares up 5%Shares of drug maker Granules India today rose by nearly 5 per cent after the US drug regulator FDA inspected its manufacturing facility.
- Sensex pares gains after rallying over 300 points; 10 stocks in focusSensex pared gains after rallying over 300 points in trade on Tuesday led by gains in Tata Motors, Hindalco, Sesa Sterlite, Cipla and Dr. R...
- USFDA reports no observations in Granules India plant; stock surgesGranules India rallied as much as 11.92% in early trade after the USFDA found no observations after inspecting its Gagillapur facility.
- USFDA inspects Gagillapur facility of Granules IndiaGranules India today said US health regulator FDA has inspected its Gagillapur manufacturing facility near Hyderabad and did not find any d...
- Granules India eyes Rs 1,000 cr turnover this fiscalMid-sized pharmaceutical company Granules India is eying to achieve Rs 1,000 crore of revenue during the current financial year 2013-14.
- Granules India gets USFDA approval for two facilitiesGranules India on Monday said two of its facilities at Gagillapur and Bonthapally have received United States Food and Drug Administration'...
Load More
